Non-Coding Rnas: Emerging Contributors to Chemoresistance in Chronic Myeloid Leukemia Publisher

Summary: Non-coding RNAs may drive resistance in chronic myeloid leukemia. What if targeting them could change treatment outcomes? Research points to new therapeutic avenues. #CML #CancerResearch

Ghadyani Nejhad L¹ ; Sohani M² ; Ghandforoush NA¹ ; Nikbakht M³ ; Mohammadi S³ ; Vaezi M⁴ ; Rostami S¹ ; Chahardouli B³
Source: Leukemia Research Reports Published:2025

Abstract

Chronic myeloid leukemia (CML), is a myeloproliferative disease characterized by unregulated growth of blood forming cells in bone marrow and blood. The t(9;22)(q34;q11.2) translocation, which results in the formation of a hyperactive tyrosine kinase (BCR-ABL), is a hallmark of this disorder. Tyrosine kinase inhibitors such as imatinib has shown a great promise in reduction of CML cells. However, development of resistance to tyrosine kinase inhibitors has raised a great clinical concern about their future applications. Recently, non-coding RNAs, have shown to play significant regulatory roles in development of chemoresistance in CML cells. Discovering the underlying mechanisms of these non-coding RNAs might provide new opportunities for treating chemo-resistant forms of CML. These non-coding RNAs could be considered valuable therapeutic targets if they are found to play a role in the development of chemoresistance in CML cells. We mentioned the identified non-coding RNAs in development of chemoresistance in CML cells. © 2025 The Authors